Sarin SK, Kumar M, Eslam M, George J, Al Mahtab M, Akbar SMF, et al. Liver diseases in the Asia-Pacific region: a Lancet Gastroenterology & hepatology Commission. Lancet Gastroenterol Hepatol. 2020;5(2):167–228

Article  PubMed  Google Scholar 

Kawaguchi T, Tsutsumi T, Nakano D, Eslam M, George J, Torimura T. MAFLD enhances clinical practice for liver disease in the Asia-Pacific region. Clin Mol Hepatol. 2022;28(2):150–163

Article  PubMed  Google Scholar 

Harbour R, Miller J. A new system for grading recommendations in evidence based guidelines. BMJ. 2001;323(7308):334–336

Article  PubMed  PubMed Central  CAS  Google Scholar 

Lim GEH, Tang A, Ng CH, Chin YH, Lim WH, Tan DJH, et al. An observational data meta-analysis on the differences in prevalence and risk factors between MAFLD vs NAFLD. Clin Gastroenterol Hepatol. 2023;21(3):619–629

Article  PubMed  Google Scholar 

Chan KE, Koh TJL, Tang ASP, Quek J, Yong JN, Tay P, et al. Global prevalence and clinical characteristics of metabolic-associated fatty liver disease: a meta-analysis and systematic review of 10 739 607 individuals. J Clin Endocrinol Metab. 2022;107(9):2691–2700

Article  PubMed  Google Scholar 

Younossi ZM, Golabi P, Paik JM, Henry A, Van Dongen C, Henry L. The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review. Hepatology. 2023;77(4):1335–1347

Article  PubMed  Google Scholar 

Danpanichkul P, Kongarin S, Permpatdechakul S, Polpichai N, Duangsonk K, Manosroi W, et al. The Surreptitious Burden of Nonalcoholic Fatty Liver Disease in the Elderly in the Asia-Pacific Region: An Insight from the Global Burden of Disease Study 2019. J Clin Med. 2023;12(20).

Chang M, Shao Z, Shen G. Association between triglyceride glucose-related markers and the risk of metabolic-associated fatty liver disease: a cross-sectional study in healthy Chinese participants. BMJ Open. 2023;13(5): e070189

Article  PubMed  PubMed Central  Google Scholar 

Chen YL, Li H, Li S, Xu Z, Tian S, Wu J, et al. Prevalence of and risk factors for metabolic associated fatty liver disease in an urban population in China: a cross-sectional comparative study. BMC Gastroenterol. 2021;21(1):212

Article  PubMed  PubMed Central  CAS  Google Scholar 

Prabhakar T, Prasad M, Kumar G, Kaushal K, Shenoy PS, Dubey S, Sarin SK. High prevalence of MAFLD in general population: A large cross‐sectional study calls for concerted public health action. Alimentary Pharmacology & Therapeutics. 2024.

Alam S, Fahim SM, Chowdhury MAB, Hassan MZ, Azam G, Mustafa G, et al. Prevalence and risk factors of non-alcoholic fatty liver disease in Bangladesh. JGH Open. 2018;2(2):39–46

Article  PubMed  PubMed Central  Google Scholar 

Kim M, Yoon EL, Cho S, Lee CM, Kang BK, Park H, et al. Prevalence of advanced hepatic fibrosis and comorbidity in metabolic dysfunction-associated fatty liver disease in Korea. Liver Int. 2022;42(7):1536–1544

Article  PubMed  Google Scholar 

Fujii H, Fukumoto S, Enomoto M, Uchida-Kobayashi S, Kimura T, Tamori A, et al. The FibroScan-aspartate aminotransferase score can stratify the disease severity in a Japanese cohort with fatty liver diseases. Sci Rep. 2021;11(1):13844

Article  PubMed  PubMed Central  CAS  Google Scholar 

Taheri E, Moslem A, Mousavi-Jarrahi A, Hatami B, Pourhoseingholi MA, Asadzadeh Aghdaei H, et al. Predictors of metabolic-associated fatty liver disease (MAFLD) in adults: a population-based study in Northeastern Iran. Gastroenterol Hepatol Bed Bench. 2021;14(Suppl1):S102–S111

PubMed  PubMed Central  Google Scholar 

Yilmaz Y, Yilmaz N, Ates F, Karakaya F, Gokcan H, Kaya E, et al. The prevalence of metabolic-associated fatty liver disease in the Turkish population: A multicenter study. Hepatol Forum. 2021;2(2):37–42

PubMed  PubMed Central  Google Scholar 

Kani HT, Demirtas CO, Keklikkiran C, Ergenc I, Mehdiyev S, Akdeniz E, et al. Evaluation of the Impact of Metabolic Syndrome on Fibrosis in Metabolic Dysfunction-Associated Fatty Liver Disease. Turk J Gastroenterol. 2021;32(8):661–666

Article  PubMed  Google Scholar 

Vaz K, Kemp W, Majeed A, Lubel J, Magliano DJ, Glenister KM, et al. Non-alcoholic fatty liver disease prevalence in Australia has risen over 15 years in conjunction with increased prevalence of obesity and reduction in healthy lifestyle. J Gastroenterol Hepatol. 2023;38(10):1823–1831

Article  PubMed  PubMed Central  CAS  Google Scholar 

Kemp W, Clayton-Chubb D, Majeed A, Glenister KM, Magliano DJ, Lubel J, et al. Impact of renaming NAFLD to MAFLD in an Australian regional cohort: Results from a prospective population-based study. J Gastroenterol Hepatol. 2022;37(2):395–403

Article  PubMed  Google Scholar 

Eslam M, Sanyal AJ, George J. Toward More Accurate Nomenclature for Fatty Liver Diseases. Gastroenterology. 2019;157(3):590–593

Article  PubMed  Google Scholar 

Eslam M, Newsome PN, Anstee QM, Targher G, Gomez MR, Zelber-Sagi S, et al. A new definition for metabolic associated fatty liver disease: an international expert consensus statement. J Hepatol. 2020.

Alharthi J, Gastaldelli A, Cua IH, Ghazinian H, Eslam M. Metabolic dysfunction-associated fatty liver disease: a year in review. Curr Opin Gastroenterol. 2022;38(3):251–260

Article  PubMed  CAS  Google Scholar 

Lee H, Lee HW, Kim SU, Chang KH. Metabolic Dysfunction-Associated Fatty Liver Disease Increases Colon Cancer Risk: A Nationwide Cohort Study. Clin Transl Gastroenterol. 2022;13(1): e00435

Article  PubMed  PubMed Central  Google Scholar 

Pan Z, Yilmaz Y, Al-Busafi SA, Eslam M. The MAFLD definition identifies three homogenous groups of patients. Liver Int. 2024;44(12):3287–3289

Article  PubMed  Google Scholar 

Eslam M, Sarin SK, Wong VW, Fan JG, Kawaguchi T, Ahn SH, et al. The Asian Pacific Association for the Study of the Liver clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease. Hepatol Int. 2020;14(6):889–919

Article  PubMed  Google Scholar 

Yuan Q, Wang H, Gao P, Chen W, Lv M, Bai S, Wu J. Prevalence and Risk Factors of Metabolic-Associated Fatty Liver Disease among 73,566 Individuals in Beijing, China. International journal of environmental research and public health. 2022;19(4).

Fan J, Luo S, Ye Y, Ju J, Zhang Z, Liu L, et al. Prevalence and risk factors of metabolic associated fatty liver disease in the contemporary South China population. Nutr Metab (Lond). 2021;18(1):82

Article  PubMed  CAS  Google Scholar 

Kim D, Chung GE, Kwak MS, Seo HB, Kang JH, Kim W, et al. Body Fat Distribution and Risk of Incident and Regressed Nonalcoholic Fatty Liver Disease. Clin Gastroenterol Hepatol. 2016;14(1):132-138.e134

Article  PubMed  Google Scholar 

Eslam M, El-Serag HB, Francque S, Sarin SK, Wei L, Bugianesi E, et al. Metabolic (dysfunction)-associated fatty liver disease in individuals of normal weight. Nat Rev Gastroenterol Hepatol. 2022;19(10):638–651

Article  PubMed  Google Scholar 

En Li Cho E, Ang CZ, Quek J, Fu CE, Lim LKE, Heng ZEQ, et al. Global prevalence of non-alcoholic fatty liver disease in type 2 diabetes mellitus: an updated systematic review and meta-analysis. Gut. 2023;72(11):2138–2148

Article  PubMed  Google Scholar 

Ampuero J, Aller R, Gallego-Durán R, Banales JM, Crespo J, García-Monzón C, et al. The effects of metabolic status on non-alcoholic fatty liver disease-related outcomes, beyond the presence of obesity. Aliment Pharmacol Ther. 2018;48(11–12):1260–1270

Article  PubMed  CAS  Google Scholar 

Ye Q, Zou B, Yeo YH, Li J, Huang DQ, Wu Y, et al. Global prevalence, incidence, and outcomes of non-obese or lean non-alcoholic fatty liver disease: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2020;5(8):739–752

Article  PubMed  Google Scholar 

Kim D, Konyn P, Cholankeril G, Ahmed A. Physical activity is associated with nonalcoholic fatty liver disease and significant fibrosis measured by FibroScan. Clin Gastroenterol Hepatol. 2022;20(6):e1438–e1455

Article  PubMed  CAS  Google Scholar 

Chun HS, Lee M, Lee HA, Oh SY, Baek HJ, Moon JW, et al. Association of physical activity with risk of liver fibrosis, sarcopenia, and cardiovascular disease in nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol. 2023;21(2):358-369.e312

Article  PubMed  CAS  Google Scholar 

Bali T, Chrysavgis L, Cholongitas E. Metabolic-associated fatty liver disease and sarcopenia. Endocrinol Metab Clin North Am. 2023;52(3):497–508

Article  PubMed  Google Scholar 

Joo SK, Kim W. Interaction between sarcopenia and nonalcoholic fatty liver disease. Clin Mole Hepatol. 2023;29(Suppl):S68-s78

Article  Google Scholar